Prognostic and predictive role of a metabolic rate‐limiting enzyme signature in hepatocellular carcinoma

Abnormal expression of metabolic rate‐limiting enzymes drives the occurrence and progression of hepatocellular carcinoma (HCC). This study aimed to elucidate the comprehensive model of metabolic rate‐limiting enzymes associated with the prognosis of HCC.

[1]  Q. Dong,et al.  Development and Validation of a Metabolic Gene-Based Prognostic Signature for Hepatocellular Carcinoma , 2021, Journal of hepatocellular carcinoma.

[2]  Jianwei Zhou,et al.  Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7 , 2020, Cell Death & Disease.

[3]  Gao-Min Liu,et al.  Identification of a four‐gene metabolic signature predicting overall survival for hepatocellular carcinoma , 2020, Journal of cellular physiology.

[4]  Ming‐Jen Chen,et al.  Targeting the pentose phosphate pathway increases reactive oxygen species and induces apoptosis in thyroid cancer cells , 2020, Molecular and Cellular Endocrinology.

[5]  Q. Ding,et al.  The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells , 2019, RNA biology.

[6]  Y. Wan,et al.  Metabolic Reprogramming in Mitochondria of Myeloid Cells , 2019, Cells.

[7]  B. Goh,et al.  Targeting Cell Metabolism as Cancer Therapy. , 2019, Antioxidants & redox signaling.

[8]  C. Frezza.  Metabolism and cancer: the future is now , 2019, British Journal of Cancer.

[9]  Baochi Ou,et al.  Polo-like kinase 3 inhibits glucose metabolism in colorectal cancer by targeting HSP90/STAT3/HK2 signaling , 2019, Journal of Experimental & Clinical Cancer Research.

[10]  D. Chiu,et al.  The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer , 2019, Cells.

[11]  Su-Jae Lee,et al.  Decreased FBP1 expression rewires metabolic processes affecting aggressiveness of glioblastoma , 2019, Oncogene.

[12]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[13]  Zhenqiang Fang,et al.  RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy , 2019, BMC urology.

[14]  P. Romero,et al.  Navigating metabolic pathways to enhance antitumour immunity and immunotherapy , 2019, Nature Reviews Clinical Oncology.

[15]  X. Wang,et al.  UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis , 2019, Nature.

[16]  R. Gedaly,et al.  Novel biomarkers in hepatocellular carcinoma. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  Wei Yu,et al.  Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway , 2018, Cancer management and research.

[18]  R. Qin,et al.  UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma , 2018, IUBMB life.

[19]  Chao Wu,et al.  RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine , 2018, OncoTargets and therapy.

[20]  Y. Zhuang,et al.  Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si‑SAΤB1 in ovarian cancer. , 2018, Oncology reports.

[21]  Hao Pan,et al.  Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro. , 2018, International journal of oncology.

[22]  C. Isacke,et al.  Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation , 2018, Nature Communications.

[23]  P. Boutros,et al.  Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer , 2018, EBioMedicine.

[24]  D. Smiraglia,et al.  Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas , 2018, Nature Communications.

[25]  Guodong Yi,et al.  Identification of a novel gene pairs signature in the prognosis of gastric cancer , 2017, Cancer medicine.

[26]  Y. Yen,et al.  Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis , 2017, Journal of breast cancer.

[27]  N. Munshi,et al.  Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma , 2017, Clinical Cancer Research.

[28]  J. Cheong,et al.  Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing cancer cell survival under metabolic stress , 2017, Nature Communications.

[29]  A. Chakravarti,et al.  Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis , 2016, Clinical Cancer Research.

[30]  Hongbing Chen,et al.  Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer , 2015, World Journal of Surgical Oncology.

[31]  R. Deberardinis,et al.  Metabolic pathways promoting cancer cell survival and growth , 2015, Nature Cell Biology.

[32]  M. Papotti,et al.  RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization , 2015, Molecular and Cellular Endocrinology.

[33]  J. Ricci,et al.  Cancer metabolism: current perspectives and future directions , 2012, Cell Death and Disease.

[34]  Ge Gao,et al.  RLEdb: a database of rate-limiting enzymes and their regulation in human, rat, mouse, yeast and E. coli , 2009, Cell Research.

[35]  Y. Murakumo,et al.  Prognostic significance of G6PD expression and localization in lung adenocarcinoma. , 2019, Biochimica et biophysica acta. Proteins and proteomics.